Fluoxetine Alternatives in Kentucky
Compare generic and therapeutic alternatives to Fluoxetine (fluoxetine) available at Kentucky pharmacies. Save up to 94% on your prescription — no insurance required.
Top Alternatives in Kentucky
Sertraline (generic Zoloft)
therapeutic
Most prescribed SSRI — comparable efficacy, similarly priced
Avg cash price: $10/mo
Escitalopram (generic Lexapro)
therapeutic
Highly selective SSRI — often preferred for fewer drug interactions
Avg cash price: $12/mo
Prozac (brand fluoxetine)
brand
Brand name — same drug at 40× the cost
Avg cash price: $320/mo
Kentucky Prescription Assistance Programs
Kentucky Medicaid (Kentucky HEALTH)
Prescription drug coverage for Kentucky Medicaid beneficiaries, including an extensive generic formulary.
Eligibility: Low-income adults, children, pregnant women, and people with disabilities meeting income requirements. Kentucky expanded Medicaid under the ACA.
Frequently Asked Questions
Is fluoxetine the same as Prozac?
Yes — fluoxetine is the generic name for Prozac. Generic fluoxetine has been available since 2001 and costs $5–$12/month versus $280–$350 for brand Prozac.
Why does fluoxetine have a long half-life?
Fluoxetine has a half-life of 1–4 days (its active metabolite norfluoxetine: 4–16 days). This makes it more forgiving of missed doses and allows once-weekly dosing in some maintenance patients — unique among SSRIs.
Is fluoxetine or sertraline better for depression?
Both show comparable antidepressant efficacy in trials. Fluoxetine is more activating and may cause initial insomnia or jitteriness. Sertraline has slightly more GI side effects. Tolerability differences guide the choice.
Does fluoxetine work for OCD?
Yes — fluoxetine is FDA-approved for OCD at doses of 40–80 mg/day, typically higher than depression doses. Response in OCD may take 8–12 weeks.
What does fluoxetine cost through Script Unlock?
Fluoxetine is one of the cheapest medications available — often $5–$10/month. Script Unlock pharmacies offer competitive cash pricing, though savings may be modest given the already-low baseline cost.